Tesamorelin vs CJC-1295 DAC.

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH/GRF 1-44), stabilized by a trans-3-hexenoic acid group attached to its N-terminus. It is one of the few research peptides in its class that holds full FDA approval, marketed as Egrifta (and the reformulated Egrifta SV / Egrifta WR) by Theratechnologies for a narrow, specific indication. Originally designated TH9507, it is a secretagogue rather than a hormone itself.

CJC-1295 with DAC (also written DAC:GRF, CJC-1295 DAC) is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). It is built on the bioactive N-terminal GHRH(1-29) fragment with several amino-acid substitutions, plus a "Drug Affinity Complex" (DAC): a maleimidopropionyl group that lets the peptide bind covalently to circulating albumin after injection. It was developed in the mid-2000s by ConjuChem Biotechnologies as an investigational drug; it is not an approved medicine and today circulates mainly as a research/gray-market peptide.

Tesamorelin binds the GHRH receptor on the anterior pituitary, stimulating the synthesis and pulsatile release of the body's own growth hormone (GH), which in turn raises hepatic and circulating insulin-like growth factor-1 (IGF-1). Because it works upstream by amplifying endogenous GH secretion, it largely preserves physiological feedback and pulsatility, unlike direct exogenous GH administration. The N-terminal hexenoyl modification confers resistance to degradation (including by dipeptidyl peptidase-IV) and extends its half-life relative to native GHRH. The downstream rise in GH/IGF-1 drives lipolysis, with a notable effect on visceral (intra-abdominal) adipose tissue.

Like native GHRH, CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of growth hormone (GH), which in turn drives hepatic and peripheral IGF-1 production. Two engineering features extend its action: amino-acid substitutions in the GHRH(1-29) backbone resist cleavage by dipeptidyl-peptidase-4 (DPP-4), and the DAC maleimide group forms a covalent bond with cysteine-34 of serum albumin, shielding the peptide from renal filtration and proteolysis so it persists in plasma for days rather than minutes. Because it amplifies the body's own GH axis rather than supplying exogenous GH, secretion remains somewhat pulsatile and subject to negative feedback (e.g., somatostatin).

Human evidence is unusually strong for one specific population: HIV patients with lipodystrophy. Two pivotal phase 3 randomized, placebo-controlled trials and their pooled analysis (Falutz et al., JAIDS 2010 and J Clin Endocrinol Metab 2010) showed roughly a 15-18% reduction in visceral adipose tissue over 26 weeks, with regain after discontinuation, supporting the FDA approval. Stanley et al. (JAMA 2014; PMID 25038357) and a randomized NAFLD trial (Stanley et al., Lancet HIV 2019; PMID 31611038) further demonstrated reductions in liver fat and a lower rate of fibrosis progression in HIV-associated fatty liver disease. Crucially, nearly all rigorous human data come from HIV-positive cohorts; use for general anti-aging, body recomposition, or NAFLD in HIV-negative people is extrapolation and has not been established in large controlled trials. Subcutaneous fat and total weight are largely unaffected, and effects reverse when treatment stops.

Human evidence comes mainly from early-phase ConjuChem trials in healthy adults. Teichman et al. (JCEM, 2006) reported that single subcutaneous doses produced dose-dependent, sustained elevations of GH and IGF-1, with IGF-1 remaining above baseline for several days and repeated weekly/biweekly dosing maintaining elevated IGF-1. Ionescu and Frohman (JCEM, 2006) showed that despite continuous GHRH-receptor stimulation, GH secretion remained pulsatile in healthy men. Preclinical support includes Alba et al. (Am J Physiol Endocrinol Metab, 2006), where once-daily CJC-1295 normalized growth in GHRH-knockout mice, and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), which characterized GH/IGF-1-axis-driven serum protein changes. Crucially, there are no published controlled trials demonstrating clinical outcomes (body composition, strength, fat loss, anti-aging, or healing) in humans; the human data establish a pharmacodynamic GH/IGF-1 effect, not proven therapeutic benefit, and the program was discontinued without an approved indication.

The most consistent documented concerns are glucose-related: because it raises GH/IGF-1, tesamorelin can worsen insulin sensitivity and glucose tolerance, and IGF-1 levels are monitored in clinical practice. Common adverse effects in trials included injection-site reactions, arthralgia, myalgia, peripheral edema, and paresthesia; hypersensitivity reactions have occurred. It is contraindicated in pregnancy and in people with active malignancy, since elevated IGF-1 is a theoretical tumor-growth concern, and in those with disrupted hypothalamic-pituitary axis (e.g., pituitary tumor/surgery, head irradiation). The NIH LiverTox database assigns it a low likelihood of causing clinically apparent liver injury. Long-term safety beyond the trial windows, and safety in non-HIV populations, remains poorly characterized.

In the short early-phase human studies, the most consistently noted effects were injection-site reactions and transient flushing; sustained IGF-1 elevation also raises theoretical concerns common to GH-axis stimulation, such as fluid retention, joint discomfort, carpal-tunnel-type symptoms, and reduced insulin sensitivity. Long-term human safety is essentially uncharacterized: no large or long-duration controlled trials were completed, and chronically elevated GH/IGF-1 is a biologically plausible (though unproven for this compound) concern for promoting growth of existing neoplasms. Real-world risk is compounded by the fact that material sold as "CJC-1295 DAC" is unregulated and may vary in purity, identity, or sterility. No dosing or administration guidance is provided here.

FDA-approved (2010, as Egrifta; reformulated as Egrifta SV in 2019 and the F8 formulation Egrifta WR in 2023) solely to reduce excess visceral abdominal fat in HIV-infected adults with lipodystrophy. All other uses are off-label, and it is a prescription drug, not a dietary supplement.

CJC-1295 (with or without DAC) is not approved by the FDA or any major regulator for any use; clinical development was discontinued and it is treated as an unapproved/investigational substance, with U.S. authorities also flagging it as unsuitable for pharmacy compounding. It is prohibited in sport at all times by the World Anti-Doping Agency as a GH-releasing factor under Category S2 of the Prohibited List.